A preliminary study of ritonavir, an inhibitor of hiv-1 protease, to treat hiv-1 infection

New England Journal of Medicine

Volumn 333, Issue 23, 1995, Pages 1534-1540

  Markowitz, Martin ^a   Saag, Michael ^a   Powderly, William G ^a   Hurley, Arlene M ^a   Hsu, Ann ^a   Valdes, Joaquin M ^a   Henry, David ^a   Sattler, Fred ^a   Marca, Anthony la ^a   Leonard, John M ^a   ho, David D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; RITONAVIR; RNA, VIRAL; THIAZOLES; TREATMENT OUTCOME; VALINE;

EID: 0028806725     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199512073332204     Document Type: Article

References (17)

1. Hirsch MS, D'Aquila RT Therapy for human immunodeficiency virus infection. N Engl J Med 1993; 328: 1686-1695
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard J, Markowitz M Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126
3. Wei X, Ghosh SK, Taylor ME, Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-122
4. Kempf D, Marsh K, Denissen J, ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A 1995; 92: 2484-2488
5. Kohl NE, Emini EA, Schleif WA, Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A 1988; 85: 4686-4690
6. Roberts NA, Martin JA, Kinchington D, Rational design of peptide-based HIV proteinase inhibitors. Science 1990; 248: 358-361
7. Erickson JW, Neidhart DJ, VanDrie J, Design, activity, and 2.8 Ã… crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990; 249: 527-533
8. Lam PYS, Jadhav PK, Eyermann CJ, Rational design of potent, bioavailable nonpeptide cyclic ureas as HIV protease inhibitors. Science 1994; 263: 380-384
9. Wlodawer A, Miller M, Jaskolski M, Conserved folding in retroviral protease: crystal structure of a synthetic HIV-1 protease. Science 1989; 245: 616-621
10. Navia MA, Fitzgerald PM, McKeever BM, Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989; 337: 615-620
11. Markowitz M, Mo H, Kempf DJ, Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995; 69: 701-706
12. Pachl C, Todd JA, Kern DG, Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 446-454
13. Cao Y, Ho DD, Todd J, Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses 1995; 11: 353-361
14. Kempf DJ, Marsh KC, Paul D, Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1991; 35: 2209-2214
15. Vacca JP, Dorsey BD, Schleif WA, L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A 1994; 91: 4096-4100
16. Eron J, Benoit S, Jemsek J, Quinn J, Fallon MA, Rubin M. A randomized double-blind multicenter comparative trial of lamivudine (3TC) monotherapy vs. zidovudine (ZDV) monotherapy vs. 3TC+ZDV combination in naive patients CD4 200-500/mm3. In: Program and abstracts of the Second National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29– February 2, 1995. Washington, D.C.: American Society of Microbiology, 1995:173. abstract.
17. Yerly S, Kaiser L, Baumberger C, Hirschel B, Perrin LH Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 358-364